Skip to content
OpenCapital
Get started

Replimune Group REPL Operating Lease Weighted Average Discount Rate Percent

Operating Lease Weighted Average Discount Rate Percent at other companies

Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
——
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
——

Other financials

Income statement

See full
Operating income-$71.9M-8.9%
Net income-$70.9M-6.9%
EPS (diluted)-$0.77+2.5%

Balance sheet

See full
Cash & equivalents$124.7M-28.3%
Total debt$79.2M+0.5%
Total equity$210.5M-56.4%
Total assets$333.6M-44.7%

Cash flow

See full
Operating cash flow-$66.0M-30.1%
CapEx$135.0K-92.5%
Free cash flow-$66.1M-25.9%

Valuation

See full
Market cap$930.59M+28.6%
Enterprise value$885.15M+28.3%

Returns & leverage

See full
Return on equity-90.9%+362pp
Debt / equity0.4×+0.2×
Current ratio5.6×-5.8×

Where this comes from

Reported directly by Replimune Group in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent.

The official record: Replimune Group’s 10-Q, filed February 3, 2026, on SEC EDGAR. View the filing →

Ask your AI about Replimune Group's operating lease weighted average discount rate percent.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Replimune Group's operating lease weighted average discount rate percent?
Replimune Group (REPL) reported operating lease weighted average discount rate percent of $0.1 in Q4 2025.
How has Replimune Group's operating lease weighted average discount rate percent changed year-over-year?
Replimune Group's operating lease weighted average discount rate percent increased by 1.0% year-over-year, from $0.1 to $0.1.